Chimerix Inc (STU:CXF)
€ 3.03 0.21 (7.45%) Market Cap: 298.58 Mil Enterprise Value: 168.48 Mil PE Ratio: 0 PB Ratio: 2.29 GF Score: 51/100

Chimerix Inc CX-01 Call Transcript

Jul 31, 2019 / 12:30PM GMT
Release Date Price: €3.67 (+19.16%)
Operator

Good morning, and welcome to the Chimerix conference call. Please be advised that today's call is being recorded at the company's request. I would now like to turn the call over to Michelle LaSpaluto from Chimerix.

Michelle LaSpaluto
Chimerix, Inc. - Executive Director of Financial Planning, Analysis & IR

Thank you. Earlier today, we issued a press release announcing Chimerix's worldwide license of CX-01 from Cantex Pharmaceuticals. The press release is available on the company's website. You may also access today's call via webcast on the Investors section of the Chimerix website. An archive of the webcast will be available approximately 2 hours after the conclusion of the event.

With me on today's call are Mike Sherman, President and Chief Executive Officer; Mike Andriole, Chief Financial and Chief Business Officer; Garrett Nichols, Chief Medical Officer; Roy Ware, Chief Manufacturing and Technology Officer; and Randall Lanier, Chief Science Officer, will be available for questions following our formal remarks.

Before we begin, I'd

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot